Dengue Moment
For a country that has lived with dengue as a seasonal inevitability, the emergence of DengiAll, India’s indigenous single-shot dengue vaccine now in advanced trials in Delhi, is more than a scientific milestone.
For a country that has lived with dengue as a seasonal inevitability, the emergence of DengiAll, India’s indigenous single-shot dengue vaccine now in advanced trials in Delhi, is more than a scientific milestone.
The World Health Organization (WHO) has donated 2,160 doses of Ebola trial vaccine to Uganda to evaluate the efficacy of the vaccine in combating the virus which in the recent outbreak has killed a health worker in Kampala, the country's capital.
Indonesia is developing a new Tuberculosis (TB) vaccine to strengthen the fight against TB, which has claimed an average of 150,000 lives annually.
The landmark trial will evaluate the efficacy of India’s indigenous tetravalent dengue vaccine, DengiAll, developed by Panacea Biotec.
Specifically, the team compared the immune responses in people who were protected against CMV infection after receiving the older vaccine.
The highest uptake has been among the frontline workers, with over 77,000 persons having received the third dose.
Quoting some media reports alleging vaccine shortage in Maharashtra, the ministry stated that such reports are incorrect.
The government said the reports used "incomplete information", sources in the Union Health ministry said.
The traders across the nation took a pledge to provide vital support to all the state governments in the prevention of Covid, where customers with no vaccination are urged to get the vaccine first.
The WHO noted that the rapid growth rate is likely to be a combination of both immune evasion and intrinsic increased transmissibility of the Omicron variant.
